173 related articles for article (PubMed ID: 34469831)
1. A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells.
Xu C; Meng F; Park KS; Storey AJ; Gong W; Tsai YH; Gibson E; Byrum SD; Li D; Edmondson RD; Mackintosh SG; Vedadi M; Cai L; Tackett AJ; Kaniskan HÜ; Jin J; Wang GG
Cell Chem Biol; 2022 Mar; 29(3):386-397.e9. PubMed ID: 34469831
[TBL] [Abstract][Full Text] [Related]
2. NSD3 in Cancer: Unraveling Methyltransferase-Dependent and Isoform-Specific Functions.
Nuñez Y; Vera S; Baeza V; Gonzalez-Pecchi V
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256018
[TBL] [Abstract][Full Text] [Related]
3. Using Chemical Epigenetics to Target Cancer.
Wimalasena VK; Wang T; Sigua LH; Durbin AD; Qi J
Mol Cell; 2020 Jun; 78(6):1086-1095. PubMed ID: 32407673
[TBL] [Abstract][Full Text] [Related]
4. The PWWP domain of the human oncogene WHSC1L1/NSD3 induces a metabolic shift toward fermentation.
Rona GB; Almeida DSG; Pinheiro AS; Eleutherio ECA
Oncotarget; 2017 Aug; 8(33):54068-54081. PubMed ID: 28903324
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation.
Wei J; Meng F; Park KS; Yim H; Velez J; Kumar P; Wang L; Xie L; Chen H; Shen Y; Teichman E; Li D; Wang GG; Chen X; Kaniskan HÜ; Jin J
J Am Chem Soc; 2021 Sep; 143(37):15073-15083. PubMed ID: 34520194
[TBL] [Abstract][Full Text] [Related]
6. Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
Xiang W; Zhao L; Han X; Qin C; Miao B; McEachern D; Wang Y; Metwally H; Kirchhoff PD; Wang L; Matvekas A; He M; Wen B; Sun D; Wang S
J Med Chem; 2021 Sep; 64(18):13487-13509. PubMed ID: 34473519
[TBL] [Abstract][Full Text] [Related]
7. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
Belcher BP; Ward CC; Nomura DK
Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
[TBL] [Abstract][Full Text] [Related]
8. Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic.
Hu Z; Crews CM
Chembiochem; 2022 Jan; 23(2):e202100270. PubMed ID: 34494353
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.
Shrestha A; Kim N; Lee SJ; Jeon YH; Song JJ; An H; Cho SJ; Kadayat TM; Chin J
J Med Chem; 2021 Oct; 64(20):14913-14929. PubMed ID: 34488340
[TBL] [Abstract][Full Text] [Related]
10. Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.
Liu XJ; Xu-Liu ; Pang XJ; -Ying Yuan X; Yu GX; Li YR; Guan YF; Zhang YB; Song J; Zhang QR; Zhang SY
Bioorg Med Chem; 2021 Oct; 47():116358. PubMed ID: 34479103
[TBL] [Abstract][Full Text] [Related]
11. Indomethacin-based PROTACs as pan-coronavirus antiviral agents.
Desantis J; Mercorelli B; Celegato M; Croci F; Bazzacco A; Baroni M; Siragusa L; Cruciani G; Loregian A; Goracci L
Eur J Med Chem; 2021 Dec; 226():113814. PubMed ID: 34534839
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel BTK PROTACs for B-Cell lymphomas.
Zhao Y; Shu Y; Lin J; Chen Z; Xie Q; Bao Y; Lu L; Sun N; Wang Y
Eur J Med Chem; 2021 Dec; 225():113820. PubMed ID: 34509879
[TBL] [Abstract][Full Text] [Related]
13. PROTAC cell permeability and oral bioavailability: a journey into uncharted territory.
Poongavanam V; Kihlberg J
Future Med Chem; 2022 Jan; 14(3):123-126. PubMed ID: 34583518
[No Abstract] [Full Text] [Related]
14. AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss.
Hati S; Zallocchi M; Hazlitt R; Li Y; Vijayakumar S; Min J; Rankovic Z; Lovas S; Zuo J
Eur J Med Chem; 2021 Dec; 226():113849. PubMed ID: 34560429
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a Novel BCL-X
Pal P; Thummuri D; Lv D; Liu X; Zhang P; Hu W; Poddar SK; Hua N; Khan S; Yuan Y; Zhang X; Zhou D; Zheng G
J Med Chem; 2021 Oct; 64(19):14230-14246. PubMed ID: 34533954
[TBL] [Abstract][Full Text] [Related]
16. Flexible Fitting of PROTAC Concentration-Response Curves with Changepoint Gaussian Processes.
Semenova E; Guerriero ML; Zhang B; Hock A; Hopcroft P; Kadamur G; Afzal AM; Lazic SE
SLAS Discov; 2021 Oct; 26(9):1212-1224. PubMed ID: 34543136
[TBL] [Abstract][Full Text] [Related]
17. Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation.
Zhang H; Han Y; Yang Y; Lin F; Li K; Kong L; Liu H; Dang Y; Lin J; Chen PR
J Am Chem Soc; 2021 Oct; 143(40):16377-16382. PubMed ID: 34596400
[TBL] [Abstract][Full Text] [Related]
18. NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis.
Sengupta D; Zeng L; Li Y; Hausmann S; Ghosh D; Yuan G; Nguyen TN; Lyu R; Caporicci M; Morales Benitez A; Coles GL; Kharchenko V; Czaban I; Azhibek D; Fischle W; Jaremko M; Wistuba II; Sage J; Jaremko Ł; Li W; Mazur PK; Gozani O
Mol Cell; 2021 Nov; 81(21):4481-4492.e9. PubMed ID: 34555356
[TBL] [Abstract][Full Text] [Related]
19. Challenges and opportunities for
Benowitz AB; Scott-Stevens PT; Harling JD
Future Med Chem; 2022 Jan; 14(3):119-121. PubMed ID: 34528453
[No Abstract] [Full Text] [Related]
20. Regulation of Fibroblast Activation Protein-α Expression: Focus on Intracellular Protein Interactions.
Juillerat-Jeanneret L; Tafelmeyer P; Golshayan D
J Med Chem; 2021 Oct; 64(19):14028-14045. PubMed ID: 34523930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
